Roles of eIF5A in the immunosurveillance of cellular senescence

por Jiang, Xiangli, Loayza-Puch, Fabricio
Publicado 2022

Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement

por Gao, Qiongqiong, Li, Pupu, Jiang, Xiangli, Zhan, Zhongli, Yan, Qingna, Zhang, Bo, Huang, Chun
Publicado 2017

Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma

por Li, Pupu, Gao, Qiongqiong, Jiang, Xiangli, Zhan, Zhongli, Yan, Qingna, Li, Zhaona, Huang, Chun
Publicado 2019

Differences in Lung Cancer Treatment Preferences Among Oncologists, Patients and Family Members: A Semi-Structured Qualitative Study in China

por He, Xiaoning, Zhang, Mengqian, Wu, Jing, Xu, Song, Jiang, Xiangli, Wang, Ziping, Zhang, Shucai, Xie, Feng
Publicado 2021

Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits

por Wu, Zhiqiang, Liu, Zhuang, Jiang, Xiangli, Mi, Zeyun, Meng, Maobin, Wang, Hui, Zhao, Jinlin, Zheng, Boyu, Yuan, Zhiyong
Publicado 2019

Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report

por Li, Zhaona, Li, Pupu, Yan, Bing, Gao, Qiongqiong, Jiang, Xiangli, Zhan, Zhongli, Yan, Qingna, Lizaso, Analyn, Huang, Chun
Publicado 2019

Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis

por Wang, Qingsong, Xu, Liang, Wang, Gang, Chen, Lei, Li, Changping, Jiang, Xiangli, Gao, Hai, Yang, Bing, Tian, Weiping
Publicado 2020

WT1‐interacting protein inhibits cell proliferation and tumorigenicity in non‐small‐cell lung cancer via the AKT/FOXO1 axis

por Wu, Zhiqiang, Qiu, Minghan, Mi, Zeyun, Meng, Maobin, Guo, Yu, Jiang, Xiangli, Fang, Jiaping, Wang, Hui, Zhao, Jinlin, Liu, Zhuang, Qian, Dong, Yuan, Zhiyong
Publicado 2019

STAT3/miR-135b/NF-κB axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer

por Zhao, Jinlin, Wang, Xin, Mi, Zeyun, Jiang, Xiangli, Sun, Lin, Zheng, Boyu, Wang, Jing, Meng, Maobin, Zhang, Lu, Wang, Zhongqiu, Song, Junwei, Yuan, Zhiyong, Wu, Zhiqiang
Publicado 2021

CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study

por Liu, Zhujun, Wang, Jing, Meng, Zhaoting, Wang, Xinyue, Zhang, Cuicui, Qin, Tingting, Chen, Jinliang, Jiang, Xiangli, Wang, Liuchun, Lin, Li, Zhang, Xiaoling, Chen, Peng, Huang, Chun, Jiang, Richeng, Li, Kai
Publicado 2018

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospecti...

por Zhang, Linlin, Wang, Liuchun, Wang, Jingya, Chen, Jinliang, Meng, Zhaoting, Liu, Zhujun, Jiang, Xiangli, Wang, Xinyue, Huang, Chun, Chen, Peng, Liang, Yan, Jiang, Richeng, Wang, Jing, Zhong, Diansheng, Shang, Yanhong, Zhang, Yan, Zhang, Cuiying, Huang, Dingzhi
Publicado 2023

Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis

por Sun, Qian, Li, Shuzhan, Wang, Yanan, Peng, Haiyong, Zhang, Xiying, Zheng, Yu, Li, Chunjia, Li, Li, Chen, Rongrong, Chen, Xinxin, Bai, Wenjing, Jiang, Xiangli, Liu, Liang, Wei, Feng, Wang, Boshi, Zhang, Yu, Li, Hui, Ren, Xiubao, Zhang, Hongbing
Publicado 2018